Biological and Clinical Factors Contributing to the Metabolic Heterogeneity of Hospitalized Patients with and without COVID-19

D’Alessandro, Angelo; Thomas, Tiffany; Akpan, Imo J.; Reisz, Julie A.; Cendali, Francesca I.; Gamboni, Fabia; Nemkov, Travis; Thangaraju, Kiruphagaran; Katneni, Upendra; Tanaka, Kenichi; Kahn, Stacie; Wei, Alexander Z.; Valk, Jacob E.; Hudson, Krystalyn E.; Roh, David; Moriconi, Chiara; Zimring, James C.; Hod, Eldad A.; Spitalnik, Steven L.; Buehler, Paul W.; Francis, Richard O.

The Corona Virus Disease 2019 (COVID-19) pandemic represents an ongoing worldwide challenge. The present large study sought to understand independent and overlapping metabolic features of samples from acutely ill patients (n = 831) that tested positive (n = 543) or negative (n = 288) for COVID-19. High-throughput metabolomics analyses were complemented with antigen and enzymatic activity assays on plasma from acutely ill patients collected while in the emergency department, at admission, or during hospitalization. Lipidomics analyses were also performed on COVID-19-positive or -negative subjects with the lowest and highest body mass index (n = 60/group). Significant changes in amino acid and fatty acid/acylcarnitine metabolism emerged as highly relevant markers of disease severity, progression, and prognosis as a function of biological and clinical variables in these patients. Further, machine learning models were trained by entering all metabolomics and clinical data from half of the COVID-19 patient cohort and then tested on the other half, yielding ~78% prediction accuracy. Finally, the extensive amount of information accumulated in this large, prospective, observational study provides a foundation for mechanistic follow-up studies and data sharing opportunities, which will advance our understanding of the characteristics of the plasma metabolism in COVID-19 and other acute critical illnesses.